Gastrointestinal complications following hematopoietic stem cell transplantations (HSCTs) are common, but it is unknown how often gastroenterology consultation (GEC) early post BMT leads to specific changes in patient management. We aimed to determine the reason(s) for GEC, the diagnoses found through GEC, whether the advice or intervention led to change(s) in management and if intervention led to any adverse outcome within the first 100 days post HSCT. We undertook a retrospective review of all patients at least 18 years old (n ‫؍‬ 197) who underwent HSCT between November 1990 and April 1998. Of these, 79 patients had 92 consultations for a total of 163 separate GE problems within the first 100 days post HSCT. Data were obtained through chart review. It was determined whether the intervention or advice given by the consultant led to actual changes in patient management or outcome. We found that the characteristics more likely to be associated with GEC included female patient vs male (P ‫؍‬ 0.03), allogeneic vs autologous transplants (P Ͻ 0.001), hematologic vs solid malignancies (P ‫؍‬ 0.006), and leukemias vs lymphomas (P ‫؍‬ 0.013). Overall, a definitive diagnosis for an identified complaint was made in 71% (range 25-87%). A change in management was effected in 54% of cases (range 0-59%). Endoscopy led to perforation and subsequent death in two patients (1.8%). Gastrointestinal disease was a direct cause of death in 2.5% of all patients. In conclusion, a definite diagnosis was reached in 71% of gastrointestinal problems and management was effected in 54% of cases. Since endoscopy was associated with a mortality of 1.8%, minimizing its use for the cases in which no impact is made, should be considered. Bone Marrow Transplantation (2001) 28, 289-294.
Gastrointestinal toxicity is common in the course of hematopoietic stem cell transplantation (HSCT) following highdose chemotherapy alone or combined with radiotherapy. Pre-transplantation radiation and chemotherapy with cytotoxic drugs commonly results in intestinal mucosal damage. Bone marrow ablation leaves patients with lowered immunologic defences and susceptible to bacterial, viral and fungal infections. Allogeneic transplantation, which is associated with a significant risk of acute graft-versus-host disease (aGVHD), increases the possibility of gastrointestinal complications.
The impact of the gastroenterologist in the evaluation and management of these patients is poorly defined. We aimed to determine the nature of requests for consultation with a gastroenterologist (GEC), what diagnoses were found through these consultations, and whether the advice or intervention undertaken by the gastroenterologist led to any changes in patient management or adverse outcomes.
Methods
The charts of 197 consecutive patients over 18 years old undergoing HSCT at the University of Manitoba between November 1990 and April 1998 were retrospectively reviewed. Data collected included the type of malignancy, preparatory chemotherapy regimens, radiation therapy fields and dosages, medications, type of hematopoietic stem cell graft (autologous bone marrow, autologous peripheral blood progenitor cells, and allogeneic bone marrow), prophylactic or active anti-GVHD medications, laboratory data, reason for consultation, timing of complication in relation to HSCT, endoscopic and histologic findings, patient outcomes and adverse events. In those patients requiring GEC, the reason(s) for GEC was recorded, as was the final diagnosis determined for each problem. After review of each case, it was determined whether the intervention or advice given by the consultant led to actual changes in patient outcome or management. A change in management was defined as initiation of new therapy, discontinuation or dose adjustment of medications, or therapeutic endoscopic intervention. Upper gastrointestinal bleeding (UGIB) refers to vomiting of old or fresh blood. Lower gastrointestinal bleeding (LGIB) refers to passage of melena or fresh blood per rectum. Table 3 Diseases for which HSCT was performed
All HSCTs No GI consult GI consult (n) (%) (%)
Hematopoietic Non- Hodgkin's lymphoma  41  73  27  Acute myeloid leukemia  39  38  62  Chronic myeloid leukemia  30  53  47  Hodgkin's lymphoma  25  71  29  Acute lymphoblastic leukemia  17  71  29  Myelodysplasia  12  58  42  Multiple myeloma  9  44  56  Aplastic anemia  9  33  67  Myelofibrosis  2  50  50  Solid tumors Embryonal or germ cell cancer 8 100 0 Breast cancer 5 100 0 
Results
In total, 197 HSCTs were performed in the study period on patients over 18 years old. A total of 92 GEC were requested on 79 of the 197 patients (40%). In total, 163 gastrointestinal problems were specified as needing to be addressed in consultation (see Table 1 ). The characteristics of these patients are shown in Tables 2 and 3 . There were no diagnoses of CMV enterocolitis made.
Significant risk factors for undergoing GEC were female gender (51% of females had GEC vs 34% of males, P ϭ 0.03) and allogeneic HSCT (52% of allogeneic transplants had GEC vs 25% of autologous transplants, P Ͻ 0.001). The disease for which the transplant was being performed also influenced the likelihood of GEC (P Ͻ 0.0001). Hematologic malignancies were at greater risk than solid malignancies (P ϭ 0.006), and patients with leukemia needed more GEC than did lymphoma patients (P ϭ 0.013).
Acute GVHD consultations
Forty-two consultations (46%) were sought on 39 patients specifically to rule out suspected aGVHD due to specific gastrointestinal symptoms (ie vomiting, diarrhea; these symptoms if specified in the consultation request are also included in separate analysis). These consultations occurred within a mean (Ϯ standard deviation) of 31 Ϯ 12 days post HSCT. Of these consultations, 16/42 (38%) were on patients who had been diagnosed with aGVHD previously in their clinical course, 11 (26%) of whom were already receiving active therapy for either presumed or documented aGVHD. A definitive diagnosis was made in 23 (55%) of the 42 GEC, 18 of whom had aGVHD (43% of consultations) ( Table 5 ). Of the 18 GEC in whom aGVHD was the diagnosis, six (33%) had previously been diagnosed with aGVHD and five (27.8%) were already being treated for GVHD. When a gastroenterologist was asked to rule out aGVHD, management was changed in 19 of 42 patients (45%) -see Table 6 .
Gastrointestinal bleeding (GIB)
Upper: Twenty-three GEC (25%) were sought on 23 patients for a complaint of upper GIB. Twenty-nine upper endoscopies were performed in this patient group in total. Bleeding occurred within a mean of 30 Ϯ 19 days of HSCT. At the time of endoscopy, mean platelet counts were 25.0 ϫ 10 9 /l Ϯ 22.7 ϫ 10 9 /l. A cause of the GIB was determined in 20 of 23 patients (87%), six of 23 (26%) were secondary to diffuse gastric bleeding. Peptic ulcers or reflux esophagitis each accounted for five (22%) of the upper GIB (Table 5) . Therapeutic hemostasis was performed nine times on seven patients (30%). Two patients required a second therapeutic intervention and therapeutic hemostasis was successful in three of seven patients (43%). Two patients required surgery, one 291 Table 5 Diagnoses found through consultation based on GI problem identified of whom subsequently died. GEC led to a change in management, either through therapeutic intervention or change in drug therapy in 13 (57%) of consults. Upper GIB was identified as the cause of death in three of the 79 patients consulted (3.8%).
Lower: Lower GIB was an uncommon complication and was a reason for GEC in only four (4%) patients. A definitive diagnosis for the lower GIB was made in only one case. GEC did not change the management in any of these cases.
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Dysphagia/Odynophagia
Eighteen (20%) GEC were for a complaint of dysphagia or odynophagia. Dysphagia or odynophagia occurred at a mean of 16 Ϯ 13 days after HSCT when the mean WBC count was 1.2 ϫ 10 9 /l Ϯ 2.2 ϫ 10 9 /l. Of the 18 patients consulted for this problem, 11 were on anti-fungal therapy and 14 were on anti-viral therapy at the time of GEC. A GEC resulted in a definitive diagnosis in 14 (78%) of these cases. The most common cause of dysphagia and odynophagia in this patient population was Candida esophagitis, Table 6 Impact of gastroenterology (GE) consultation in HSCT 
107 (66) 84 (52) with nine (50%) patients showing either typical changes of Candida esophagitis on endoscopy, and/or biopsy findings consistent with this diagnosis. Of those diagnosed with Candida esophagitis, 4/9 were on no anti-fungal therapy and were subsequently started on fluconazole. GEC led to a subsequent change in management in 10 (56%) of these cases. The patients were sub-analyzed according to whether their predominant symptom was odynophagia or dysphagia. Of those with dysphagia (n ϭ 12), five had Candida esophagitis, two had reflux esophagitis and chemotherapyinduced and radiation-induced esophagitis each accounted for one patient. Of interest, only one of these five patients with Candida esophagitis was on anti-fungal therapy at the time of consultation. In contrast, all patients with odynophagia (n ϭ 6) were receiving anti-fungal therapy prior to consultation. Four of these patients (67%) had Candida esophagitis and one had radiation esophagitis. Although already on anti-fungal therapy, two patients with odynophagia had their anti-fungal therapy intensified after consultation (nystatin and ketoconazole therapy was changed to fluconazole).
Vomiting
Vomiting was a problem in 27 (29%) of the GEC and occurred within 26 Ϯ 15 days of HSCT. A definitive diagnosis was determined for the vomiting in 19 (70%) of patients, with the most common etiology being aGVHD (nine patients, 37%). Consultation led to a change in patient management in 16 (59%) of patients.
Diarrhea
Thirty-three (36%) of the GEC sought on 31 patients included a complaint of diarrhea. Two patients had GEC for diarrhea twice. Diarrhea consultations occurred 29 Ϯ 11 days after HSCT. GEC made a definitive diagnosis to explain the diarrhea in 19 (58%) of cases, with aGVHD accounting for the majority of these diagnoses (Table 5) . GEC led to a change in management in 15 (45%) consultations.
Abdominal pain
Twelve (13%) of the consultations sought on 11 patients included a complaint of abdominal pain. GEC was able to make a diagnosis to explain the abdominal pain in eight (67%) cases, although no single diagnosis was identified as being significantly more frequent. GEC changed management in 67% of consultations.
Anorexia
Four (4%) of the GEC sought on four patients included a complaint of anorexia. Gastroenterology was able to make a diagnosis to explain the anorexia in three (75%) of the patients, with aGVHD being responsible for half of these complaints (n ϭ 2). Management was changed in 75% of cases.
Overall
Overall, a definite diagnosis was reached in 66% of gastrointestinal problems and management was effected in 52% of cases.
Complications
A total of 113 endoscopies were performed -76 gastroscopies, 21 flexible sigmoidoscopies, and 16 colonoscopies. Complications from endoscopic interventions were identified in two patients (1.8% of procedures). Duodenal perforation complicated therapeutic endoscopy in one patient after epinepherine was injected into a 2 cm, actively bleeding duodenal ulcer. The patient died due to intraperitoneal hemorrhage from the necrotic duodenal bulb and aspiration of stomach contents after undergoing duodenectomy and gastrojejunostomy. A second patient died from gramnegative sepsis 1 month after a flexible sigmoidoscopy to investigate for a complaint of diarrhea and GVHD. At autopsy, the cause of death was determined to be an intraabdominal abscess secondary to a perforation of the sigmoid colon.
Deaths
Deaths were attributed to a gastrointestinal complaint in five patients (2.5%, 5/197). In addition to the two adverse outcomes, two patients died of diffuse GI bleeding, and one from extensive small bowel infarction in a patient with cardiac tamponade.
Discussion
Gastroenterology complications early after HSCT are common, but the impact of a gastroenterologist in the evaluation and management of these patients is not well defined. Elsewhere, HSCTs are complicated by GIB in 7-18% of HSCT cases. [1] [2] [3] [4] In studies addressing causes of GIB, the most common causes are GVHD (up to 60%), 5 diffuse mucosal bleeding (65-69%), 1, 4 and esophagitis (up to 92%). 2 Duodenal and gastric ulcers are uncommon early post HSCT and account for only 6-10% of cases of UGI bleeds. 4, 5 Although endoscopy may identify the cause of upper GIB in up to 91% 4 (a study looking only at 'gross GIB'), the majority of causes of bleeding are not amenable to endoscopic treatment. Several studies have therefore concluded that endoscopy is not useful as a therapeutic endeavour. 1, 2, 4 In a study evaluating the risk of generalized bleeding in this patient population, Nevo et al 6 found moderate to severe GIB complicated 14% of their cases. They found that bleeding in general was more prevalent in patients with allogeneic and unrelated stem cell transplants compared to autologous transplants. Bleeding was determined to be an indicator of poor prognosis, but was not a direct cause of death in the majority of cases. GIB is an indicator of poor prognosis in patients requiring ICU admission after HSCT, 7 but death due to GIB occurs in only about 0.2-3% of cases. 1, 5 In our study, GIB occurred in 12% (23/197) of patients undergoing HSCT. As in previous studies, the most common reason for GI bleeding was secondary to diffuse mucosal hemorrhage (26%) with reflux esophagitis and peptic ulcer disease each being the cause of upper GI bleeding in 22% of cases. Therapeutic intervention was attempted in 30% of cases of upper GI bleeding and was successful in controlling bleeding in 13% of these cases. In addition to being a successful intervention in some patients, endoscopy resulted in a substantial impact on patient management in GI bleeding, with 87% of cases having an identifiable lesion and 56% having their management affected by endoscopic intervention. We feel this is a sufficient success rate to warrant pursuing upper endoscopy.
The incidence of odynophagia and dysphagia is about 5% 4 in patients undergoing HSCT. Historically, common causes of these complaints were either infectious esophagitis or chemo/radiotherapy-induced esophagitis. In an early study, McDonald et al 8 found 54% of patients with symptoms had esophageal infection, the majority of which were virus induced. Wheeler et al 9 showed that 47% of patients with dysphagia had fungal infections while 13% had viral infections. A more recent study by Vishny et al 2 showed a reduced incidence of viral esophagitis, presumably due to prophylactic acyclovir, with all cases of odynophagia being attributed to at least grade III to IV esophagitis. Seventysix percent of those patients had chest radiotherapy previously, only 27% had documented fungal infections, and no cases of viral esophagitis were identified. Another recent study by Johnson et al 4 showed that infective esophagitis (Candida or viral) accounted for 26% of patients with odynophagia in a study able to determine a cause of odynophagia in 79% of cases.
Our study was able to determine the cause of dysphagia and odynophagia in 78% of cases. Fifty percent of the cases of odynophagia and dysphagia in this study were secondary to fungal infection and no cases of viral esophagitis were found. Again, this may reflect the fact that these patients received prophylactic acyclovir therapy (78% were still on anti-viral therapy at time of consultation), but only 5/9 were still receiving anti-fungal therapy.
Prophylactic fluconazole has been shown to decrease the risk of both systemic and superficial fungal infections in Bone Marrow Transplantation HSCT patients. 10 Fungal esophagitis occurred in only 1% of patients undergoing HSCT in this study, despite the fact that we do not uniformly provide fluconazole prophylaxis. Of interest was the fact that Candida caused the majority of cases of dysphagia, and that in contrast to patients with odynophagia, the majority were not receiving anti-fungal therapy. The majority of patients with odynophagia and dysphagia in our study had a fungal cause and it is possible that institution of anti-fungal therapy prior to endoscopy would be cost effective for management of this complication by reducing the need for endoscopy. Endoscopy perhaps should be reserved for those patients who do not respond to fluconazole therapy.
The majority of cases of persistent nausea and vomiting post HSCT are secondary to aGVHD. Wu et al 11 found that 81% cases of persistent nausea and vomiting were due to aGVHD, although elsewhere GVHD accounted for as few as 26% of nausea and vomiting. 12 In our study, as in previous studies, this complication occurred at a mean of 26 Ϯ 15 days, and aGVHD accounted for 37% of cases. Esophagitis was responsible for the majority of the remaining cases (19%).
Acute diarrhea after HSCT is common and is a complication in up to 43% of patients post HSCT. 13 A study addressing causes of acute diarrhea in this patient population showed that acute GVHD accounted for 48% of cases, while infectious diarrhea (C. difficile, astrovirus and adenovirus) accounted for 13%. Despite extensive investigation, no clear etiology could be found for 39% of their cases of self-limiting diarrhea. Diarrhea has been a reason for GEC elsewhere in 9% of cases. 4 Previous studies have shown that the most likely etiology for diarrhea post HSCT is aGVHD (48-52%). 4, 13 In our study, we found 58% of diarrhea cases had an identifiable etiology. The majority of identified cases were acute aGVHD (42%).
Most of the gastroenterology consultations included endoscopy (91%) and most endoscopies were associated with biopsies (83%). The complication rate after upper endoscopy of 1.8% must be viewed in the context of the nature of the patient population (typically immunosuppressed with severe thrombocytopenia). This rate is much higher than the complication rate in immunocompetent patients (0.01-1%). 14, 15 One of the complications occurred after therapeutic endoscopy for a bleeding lesion and one was a perforation after a flexible sigmoidoscopy. This complication rate needs to be assessed in the context of the patient's ability to withstand emergency surgical intervention.
Further exploration is required in order to determine whether empiric therapy would be useful in minimizing endoscopic therapy in these patients. For instance, the majority of patients with dysphagia have Candida esophagitis. Endoscopy could potentially be reduced by empirically treating odynophagia or dysphagia with fluconazole and reserving endoscopy for those patients who fail to improve after 48 h. In summary, gastrointestinal complications requiring GEC occur in approximately 40% of patients with HSCT within the first 100 days. Although GEC affects management in at least half of the cases, further study is required to look at whether endoscopy could be minimized in this patient population.
